Patrick Chen, MD
Internal Medicine · Salinas, CANPI 1598749616
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 217 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by AbbVie at 32.2% of the total. Reporting peaked in 2023 at $1,194 and has fallen 83.2% since, to $200 in 2025. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 217 payments — averaging $18.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amgen$396
- GSK$336
- Abbott$279
- Sanofi-aventis U.S. LLC$272
- Lilly USA, LLC$241
- plus $1K from 22 others
Across 3 payments — averaging $3033.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Avita Medical Americas, LLC$9K
What the payments were for
- Food & beverage$4,107100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 71 | $1,322 |
| Amgen(2 entities) | 21 | $396 |
| GSK | 23 | $336 |
| Abbott | 12 | $279 |
| Sanofi-aventis U.S. LLC | 11 | $272 |
| Lilly USA, LLC | 13 | $241 |
| Novo Nordisk | 12 | $214 |
| Pfizer | 8 | $158 |
| Bayer | 6 | $134 |
| AstraZeneca | 6 | $97 |
| Idorsia Pharmaceuticals US Inc | 4 | $80 |
| Viiv Healthcare Company | 4 | $68 |
| E.r. Squibb & Sons, L.L.C. | 4 | $68 |
| Merck | 3 | $59 |
| Mylan Specialty L.p. | 2 | $55 |
| Johnson & Johnson | 2 | $47 |
| Dexcom, Inc. | 3 | $43 |
| Boehringer Ingelheim | 2 | $39 |
| Myriad Women's Health, Inc. | 1 | $26 |
| Shire North American Group Inc | 1 | $25 |
| Boston Scientific | 1 | $22 |
| Embecta Corp. | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Bigfoot Biomedical Inc | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
How this compares
$4,107 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 30 | $54,652 |
| OzempicSemaglutide | 38 | $47,255 |
| JardianceEmpagliflozin | 26 | $41,568 |
| JanuviaSitagliptin Phosphate | 23 | $31,982 |
| TrulicityDulaglutide | 20 | $27,440 |
| VeltassaPatiromer Calcium Sorbitex | 13 | $21,929 |
| EliquisApixaban | 12 | $14,799 |
| LinzessLinaclotide | 12 | $13,256 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $6,433 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $5,745 |
| Atorvastatin Calcium | 526 | $4,790 |
| SynthroidLevothyroxine Sodium | 67 | $4,704 |
| Serevent DiskusSalmeterol Xinafoate | 11 | $4,526 |
| Levothyroxine Sodium | 295 | $4,166 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $3,905 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $241 | $82,09250 claims |
| Novo NordiskOzempic | $214 | $47,25538 claims |
| Boehringer IngelheimJardiance | $39 | $41,56826 claims |
| MerckJanuvia | $59 | $31,98223 claims |
| AbbVieLinzess, Synthroid | $1,322 | $17,96079 claims |
| PfizerEliquis | $158 | $14,79912 claims |
| GSKBreo Ellipta, Incruse Ellipta | $336 | $9,65029 claims |
| AstraZenecaSymbicort | $97 | $6,43318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Salinas
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.